Roche cancer immunotherapy Tecentriq wins EU approval – WHTC
|
Roche cancer immunotherapy Tecentriq wins EU approval
WHTC ZURICH (Reuters) – Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said. The European Commission approved Tecentriq, also known as atezolizumab, as a … |
